However, despite the initial response, many patients eventually develop acquired resistance to EGFR-TKIs, leading to tumor relapse, treatment failure, and shortened survival, which largely limit the application of EGFR-TKIs in NSCLC treatment [8,11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.